Swedish clinical-stage cell therapy company NextCell Pharma AB (STO:NXTCL) said on Tuesday that it has entered a strategic collaboration with Fujifilm Irvine Scientific Inc to combine their respective strengths in mesenchymal stromal cells (MSCs) and life science raw materials.

The partnership aims to offer researchers in the cell therapy sector a comprehensive solution that includes standardised MSC products, optimised culture media and cryopreservation technologies.

In 2024, NextCell Pharma expanded its commercial portfolio by developing a research-use-only umbilical cord MSC product using proprietary in-house processes. The collaboration will integrate this MSC product with Fujifilm Irvine Scientific's established media and cryopreservation product lines.

Fujifilm Irvine Scientific brings over five decades of experience in cell culture innovation, with a focus on advancing cell and gene therapy applications.

This joint offering is expected to support industry stakeholders with consistent MSC reference material and robust tools for therapy development and validation.

NextCell Pharma's leadership highlighted the partnership as a significant step in its business growth strategy and a foundation for long-term collaboration.